본 보고서는 만성 특발성 변비를 상세하게 조사하여 변비의 유병자 총수, 만성 특발성 변비의 진단이 끝난 유병자 수, 성, 연령, 치료별 증례 수 등 과거 및 장래의 역학 데이터를 제시하고 있습니다. 게다가 환자 집단과 관련된 다각적인 측면으로서 진단 프로세스, 처방 패턴, 의사의 견해, 시장 접근, 치료 옵션, 장래 시장 동향 등을 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본의 주요 7시장을 대상으로 2020년부터 2034년까지의 기간으로 분석했습니다. 또한 현행 치료 실태와 미충족 요구를 종합적으로 평가하여 시장의 잠재력과 새로운 사업 기회를 명확히 하고 있습니다.
DelveInsight's comprehensive report titled "Chronic Idiopathic Constipation - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of chronic idiopathic constipation. The report presents historical and projected epidemiological data covering total prevalent cases of constipation, total diagnosed prevalent cases of chronic idiopathic constipation, gender-specific cases of chronic idiopathic constipation, age-specific cases of chronic idiopathic constipation, and treated cases of chronic idiopathic constipation. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.
The report analyzes the existing treatment practices and unmet medical requirements in chronic idiopathic constipation. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Chronic Idiopathic Constipation Overview
Chronic idiopathic constipation is a condition without any known cause or identified underlying illness. Constipation is a condition which can be defined as a state of unsatisfactory defecation, with characteristic features of infrequent stools and difficulty in passing stools, or both. It is called idiopathic because the cause of this type of constipation is unknown and it is not caused by underlying illness or medication.
Chronic Idiopathic Constipation Diagnosis and Treatment Algorithm
Diagnosis of chronic idiopathic constipation is primarily clinical and is made after ruling out secondary causes of constipation. According to the Rome IV criteria, a patient is diagnosed with CIC if they have experienced at least two of the following symptoms for at least three months, with symptom onset at least six months prior: straining during defecation, lumpy or hard stools, a sensation of incomplete evacuation, a feeling of anorectal blockage, manual maneuvers to assist defecation, or fewer than three spontaneous bowel movements per week. Additionally, patients should not meet the criteria for irritable bowel syndrome with constipation (IBS-C), as CIC is characterized by minimal or no abdominal pain and primarily involves bowel movement difficulties.
The treatment of chronic idiopathic constipation follows a stepwise approach, beginning with lifestyle and dietary modifications such as increased fiber intake, adequate hydration, regular physical activity, and consistent toilet habits. If these measures are insufficient, over-the-counter osmotic laxatives like polyethylene glycol (PEG 3350), magnesium hydroxide, or lactulose are commonly used, with PEG being the most widely recommended due to its proven safety and efficacy. For patients with persistent symptoms, prescription therapies are considered, including lubiprostone, linaclotide, plecanatide, and prucalopride, each targeting fluid secretion or motility through distinct mechanisms. In cases where constipation is refractory to medical therapy, especially if pelvic floor dysfunction is suspected, anorectal biofeedback therapy becomes essential. Surgery is rarely needed and reserved for severe, well-characterized cases of colonic inertia that do not respond to medical or behavioral interventions. Overall, treatment is individualized, aiming to restore regular bowel function and improve quality of life.
The epidemiology section of the chronic idiopathic constipation market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of chronic idiopathic constipation. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
The epidemiology of chronic idiopathic constipation is expected to change during the forecast period (2025-2034).
The chronic idiopathic constipation therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025-2034).
With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the chronic idiopathic constipation in the 7MM is expected to change significantly during the forecast period 2025-2034.
Marketed Chronic Idiopathic Constipation Drugs
MOTEGRITY (prucalopride): Takeda
MOTEGRITY is a selective serotonin-4 (5-HT4) receptor agonist approved by the FDA in December 2018 for the treatment of chronic idiopathic constipation (CIC) in adults. It works by enhancing colonic peristalsis, thereby increasing bowel motility and promoting more regular spontaneous bowel movements. Clinical trials have shown that approximately 20-38% of patients treated with prucalopride achieve three or more complete spontaneous bowel movements (CSBMs) per week, compared to 10-20% in placebo groups.
TRULANCE (plecanatide): Bausch
TRULANCE is a guanylate cyclase-C (GC-C) agonist FDA-approved in January 2017 for the treatment of chronic idiopathic constipation in adults. It mimics the endogenous peptide uroguanylin, increasing cyclic GMP levels in the intestinal epithelium to stimulate chloride and bicarbonate secretion, thereby softening stool and accelerating transit through the colon. TRULANCE comes in a 3 mg oral tablet that may be taken with or without food. A boxed warning highlights the significant risk of dehydration in pediatric patients younger than six years of age, and use is not recommended in patients under 18 years due to lack of safety data and potential risk
Chronic Idiopathic Constipation Market Segmentation
DelveInsight's 'Chronic Idiopathic Constipation - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future chronic idiopathic constipation market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Chronic Idiopathic Constipation Market Size by Countries
The chronic idiopathic constipation market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) chronic idiopathic constipation market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments.
Chronic Idiopathic Constipation Market Size by Therapies
Chronic Idiopathic Constipation Market Size by Therapies categorized the current markets by available therapies for the study period 2020-2034.
This section focuses on the sales uptake of potential chronic idiopathic constipation drugs that have recently been launched or are anticipated to be launched in the chronic idiopathic constipation market between 2020 and 2034. It estimates the market penetration of chronic idiopathic constipation drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the chronic idiopathic constipation market.
Chronic Idiopathic Constipation Market Access and Reimbursement
DelveInsight's 'Chronic Idiopathic Constipation - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of chronic idiopathic constipation. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current chronic idiopathic constipation market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the chronic idiopathic constipation domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or chronic idiopathic constipation market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the chronic idiopathic constipation unmet needs.
Chronic Idiopathic Constipation: KOL Insights
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Mercer University, US, University Hospital Tubingen, Germany, University of Barcelona, Barcelona, Spain, ellvitge-Idibell University Hospital, Barcelona, Spain, University of Leeds, Leeds, UK, and University of Occupational and Environmental Health, Japan, among others.
"In rare circumstances, for patients who continue to have disabling constipation despite trying all medical therapies available, surgery to remove the colon may be considered. In many of these cases, the person has compromised colonic motility that doesn't respond to other treatments."
"While current therapies-including GC-C agonists, 5-HT4 agonists, and chloride channel activators-have expanded our treatment options for chronic idiopathic constipation, many patients still report suboptimal relief."
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the chronic idiopathic constipation Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
The primary treatment goals for chronic idiopathic constipation are to improve the frequency and consistency of bowel movements, reduce straining and discomfort during defecation, and alleviate associated symptoms such as bloating and abdominal discomfort. Effective treatment should also aim to enhance the patient's overall quality of life by restoring a sense of normal bowel function, minimizing reliance on laxatives, and preventing complications related to chronic constipation.
Managing chronic idiopathic constipation presents several challenges, including the heterogeneous nature of the condition, variability in patient response to therapy, and the limited long-term efficacy of many available treatments. Despite multiple approved agents, a significant proportion of patients continue to experience incomplete symptom relief or intolerable side effects, leading to dissatisfaction and frequent switching between therapies. Additionally, overlapping symptoms with other gastrointestinal disorders, such as IBS-C, can complicate diagnosis and treatment selection. Patient adherence is also a concern, especially when lifestyle modifications or behavioral strategies are required alongside pharmacologic therapy.
The chronic idiopathic constipation treatment market is being driven by a convergence of rising prevalence particularly due to an aging population and sedentary lifestyles, alongside growing public and physician awareness of gastrointestinal health, which is increasing diagnosis and demand for treatments. In addition, the expanding availability of over the counter options and elevated healthcare spending, especially in developed regions, enhance access and coverage for therapies.
The chronic idiopathic constipation Market and Epidemiology Forecast Report will benefit clients by providing a comprehensive analysis of disease prevalence, patient segmentation, treatment patterns, and market trends across key geographies, enabling data-driven decision-making for strategic planning and portfolio optimization. It offers insights into therapies, unmet needs, and competitive dynamics, helping pharmaceutical companies identify growth opportunities, prioritize R&D investments, and assess commercial potential. Additionally, the report supports forecasting and market access strategies by incorporating epidemiological projections, regulatory landscapes, and pricing benchmarks.